- Home
- XGN vs OCUP Comparison
XGN vs OCUP Comparison
Compare XGN & OCUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- OCUP
- Stock Information
- Founded
- XGN 2002
- OCUP 2018
- Country
- XGN United States
- OCUP United States
- Employees
- XGN N/A
- OCUP N/A
- Industry
- XGN Medical Specialities
- OCUP Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- OCUP Health Care
- Exchange
- XGN Nasdaq
- OCUP Nasdaq
- Market Cap
- XGN 49.4M
- OCUP 53.1M
- IPO Year
- XGN 2019
- OCUP N/A
- Fundamental
- Price
- XGN $2.71
- OCUP $1.22
- Analyst Decision
- XGN Buy
- OCUP Strong Buy
- Analyst Count
- XGN 1
- OCUP 3
- Target Price
- XGN $7.00
- OCUP $18.67
- AVG Volume (30 Days)
- XGN 25.4K
- OCUP 90.4K
- Earning Date
- XGN 11-11-2024
- OCUP 11-11-2024
- Dividend Yield
- XGN N/A
- OCUP N/A
- EPS Growth
- XGN N/A
- OCUP N/A
- EPS
- XGN N/A
- OCUP N/A
- Revenue
- XGN $56,660,000.00
- OCUP $16,449,000.00
- Revenue This Year
- XGN $9.98
- OCUP N/A
- Revenue Next Year
- XGN $13.63
- OCUP $258.69
- P/E Ratio
- XGN N/A
- OCUP N/A
- Revenue Growth
- XGN 7.05
- OCUP N/A
- 52 Week Low
- XGN $1.30
- OCUP $1.15
- 52 Week High
- XGN $3.71
- OCUP $3.40
- Technical
- Relative Strength Index (RSI)
- XGN 41.39
- OCUP 44.79
- Support Level
- XGN $2.90
- OCUP $1.24
- Resistance Level
- XGN $3.03
- OCUP $1.34
- Average True Range (ATR)
- XGN 0.19
- OCUP 0.08
- MACD
- XGN -0.04
- OCUP 0.00
- Stochastic Oscillator
- XGN 12.80
- OCUP 12.00
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.